Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA removes partial clinical hold on ipafricept

Sep. 8, 2014

FDA awards pembrolizumab accelerated approval for melanoma

Sep. 5, 2014

XBiotech reports phase III data for Xilonix in colorectal cancer

Sep. 4, 2014

Opdivo launched in Japan for unresectable melanoma

Sep. 3, 2014

FDA removes partial clinical hold on vantictumab trials

Sep. 1, 2014

AstraZeneca's MEDI-4736 to be studied in immunological subsets of advanced colorectal cancer

Aug. 29, 2014

OncoPep completes financing round to support development of MM vaccine

Aug. 29, 2014

Lilly to initiate clinical study of cancer candidate LY-3164530

Aug. 29, 2014

Innate Pharma's IPH-4102 receives E.U. orphan drug status for cutaneous T-cell lymphoma

Aug. 27, 2014

Patrys plans phase Ib/II study of PAT-SM6 with carfilzomib in multiple myeloma

Aug. 27, 2014

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...